首页 > 市场调查报告书 > 製药

药物开发

市场调查报告书

商品编码

1378605

尿失禁治疗药物市场：按失禁类型、按药物类别、按配销通路、按地区

Urinary Incontinence Treatment Drugs Market, By Incontinence Type, By Drug Class, By Distribution Channel, By Geography

出版日期: 2023年10月16日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2023年全球尿失禁药物市场规模为44.1亿美元，预测期间（2023-2030年）年复合成长率为3.4%。

报告范围		报告详情
基准年	2022年	2023年市场规模	44.1亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	3.40%	2030年市场规模预测	55.6亿美元

图 1. 2023 年尿失禁药物的全球市场占有率（按失禁类型）

尿失禁意味着膀胱失控且不自主地漏尿。在这种情况下，尿道括约肌的控制减弱或完全丧失，导致患者排尿时没有排尿的衝动。这是一个非常常见且常常令人尴尬的问题。排尿时，尿道周围的肌肉放鬆，尿液被排放体外，但尿失禁时，尿道周围的肌肉无法正常运作，导致尿液漏出。尿失禁可能是由日常生活习惯、潜在疾病或身体问题引起的。尿失禁有多种类型，包括压力性尿失禁（膀胱压力）、尿急性尿失禁（强烈排尿慾望）和溢尿性尿失禁（慢性闭尿症）。尿失禁的严重程度取决于健康状况，如尿道感染(UTI)、便秘和尿失禁。尿失禁在老年族群中较常见。

市场动态

新兴市场的主要参与者正在专注于开发具有成本效益的解决方案。因此，市场上新的先进产品的推出预计将在预测期内推动全球尿失禁药物市场的成长。例如，2023年3月15日，大型製药公司MSN Laboratories宣布推出全球首个生物等效仿製富马酸非索罗定药物Fesobig。 Fesobig被多项国际治疗指南推荐为治疗膀胱过动症（OAB）和尿失禁（UI）最安全、新颖的第一线药物。该公司正在确保这种药物价格实惠，以便使许多患者受益。膀胱过动症（OAB）是一种由骨盆底功能障碍引起的非自愿性尿失禁，多见于女性。印度尿失禁的盛行率也较高，农村地区为10%，都市区为34%。虽然尿失禁不会危及生命，但它会导致不适、羞耻和丧失自信。

本研究的主要特点

本报告对全球尿失禁治疗市场进行了详细分析，并列出了以2022年为基准年的预测期（2023-2030年）的市场规模和復合年度（年复合成长率）。
它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
它根据公司亮点、产品系列、主要亮点、业绩和策略等参数，介绍了全球尿失禁治疗药物市场的主要企业。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
全球尿失禁治疗药物市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
透过用于分析全球尿失禁治疗药物市场的各种策略矩阵，将有助于相关人员做出决策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 4.41 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	3.40%	2030 Value Projection:	US$ 5.56 Bn

Urinary incontinence means losing control of bladder that leads to involuntary leakage of urine. In this condition, control over the urinary sphincter is weakened or completely lost, and thus, a person urinates even when they do not want to. This is a very common and often embarrassing problem for people. At the time of urination, muscles around urethra relax and let urine pass out of the body, however, in urinary incontinence, muscles around urethra do not work in the way they should, and resulting in leak of urine. Urinary incontinence can be caused by everyday habits, underlying medical conditions, or physical problems. There are various type of incontinences such as stress (bladder is under pressure), urge (intense urge to pass urine), and overflow (chronic urinary retention). The severity of urinary incontinence varies as per the health conditions such as urinary tract infection (UTI), constipation, and urinary incontinence . Urinary incontinence is found more in geriatric population.

Market Dynamics

Key players in the market are focusing on the development of cost efficient solutions. Thus, introduction of new and advanced products in the market is expected to drive growth of the global urinary incontinence treatment drugs market over the forecast period. For instance, on March 15, 2023, MSN Laboratories, a leading pharmaceutical company, announced the launch of Fesobig, the world's first bioequivalent generic version of fesoterodine fumarate. Fesobig is recommended by various international treatment guidelines for the treatment of overactive bladder (OAB) and urinary incontinence (UI), as the safest and novel first-line pharmacotherapy option. The company have ensured that the drug has an affordable price so that it can benefit a large majority of patients. As overactive bladder (OAB) is an involuntary loss of urine due to pelvic floor dysfunction, which is strongly associated with the female population. The prevalence of urinary incontinence in India is also relatively high, ranging from 10% in rural areas to 34% in urban areas. Although urinary incontinence is not a life-threatening condition, it causes discomfort, embarrassment and a loss of self-confidence.

Key features of the study:

This report provides an in-depth analysis of the global urinary incontinence treatment drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global urinary incontinence treatment drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Sanofi S.A., IXALTIS, Bayer AG, elicept Therapeutics, Taiho Pharmaceutical, Cook MyoSite and Urovant Sciences GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global urinary incontinence treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary incontinence treatment drugs market

Global Urinary Incontinence Treatment Drugs Market Detailed Segmentation:

By Incontinence Type:
- Urge Incontinence
- Stress Incontinence
- Over-flow Incontinence
- Mixed Incontinence
- Other Incontinence Type
By Drug Class:
- Anticholinergic/Antispasmodic Agents
- Skeletal Muscle Relaxants
- Antidepressants
- Alpha Blockers
- Topical Estrogens
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles
- Johnson & Johnson
- Pfizer Inc.
- Astellas Pharma, Inc.
- Allergan, Inc.
- Takeda Pharmaceutical Company Limited
- Merck & Co., Inc.
- Sanofi S.A.
- IXALTIS
- Bayer AG
- elicept Therapeutics
- Taiho Pharmaceutical
- Cook MyoSite
- Urovant Sciences GmbH

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Incontinence Type
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Recent Trends
Recent Launches/Approvals
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
PORTER's Analysis

4. Global Urinary Incontinence Treatment Drugs Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type, 2018- 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Urge Incontinence
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Stress Incontinence
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Over-flow Incontinence
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Mixed Incontinence
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Other Incontinence Type
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends

6. Global Urinary Incontinence Treatment Drugs Market, By Drug Class, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Anticholinergic/Antispasmodic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Skeletal Muscle Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Alpha Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Topical Estrogens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends

7. Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global Urinary Incontinence Treatment Drugs Market, By Region, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Incontinence Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Incontinence Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Incontinence Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Incontinence Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Incontinence Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Incontinence Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 -2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Johnson & Johnson
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Pfizer Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Astellas Pharma, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Allergan, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Takeda Pharmaceutical Company Limited
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Merck & Co., Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Sanofi S.A.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- IXALTIS
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Bayer AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- elicept Therapeutics
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Taiho Pharmaceutical
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Cook MyoSite
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Urovant Sciences GmbH
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Analysts' Views

10. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

尿失禁治疗药物市场：按失禁类型、按药物类别、按配销通路、按地区

Urinary Incontinence Treatment Drugs Market, By Incontinence Type, By Drug Class, By Distribution Channel, By Geography

市场动态

本研究的主要特点

目录

第1章调查目的和假设

第2章市场展望

第3章市场动态、法规及趋势分析

第4章全球尿失禁治疗药物市场 - COVID-19 的影响分析

第5章2018-2030年全球尿失禁治疗药物市场（按失禁类型）

第6章全球尿失禁治疗药物市场，依药物类别，2018-2030

第7章全球尿失禁治疗药物市场，依配销通路，2018-2030

第8章2018-2030年全球尿失禁治疗药物市场（按地区）

第9章竞争形势

第10章章